⏳ Fetching live dividend data...
Home › Calculator › BPMC Dividend Calculator 2026
Blueprint Medicines Corporation · NASDAQ
Price: $129.46 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in BPMC → $10.40M in 10 years · $13.07/month
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open BPMC position with:
Real after-tax yield depends on where you live and how you hold BPMC.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 1.54% | -1.26% | $154 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1.31% | -1.49% | $131 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1.23% | -1.57% | $123 / yr |
| 🇬🇧 UK ISA | 0% | 1.54% | -1.26% | $154 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1.41% | -1.39% | $141 / yr |
| 🇨🇦 TFSA | 0% | 1.54% | -1.26% | $154 / yr |
| 🇨🇦 CA Taxable | 25% | 1.16% | -1.64% | $116 / yr |
| 🇦🇺 Super (pension) | 15% | 1.31% | -1.49% | $131 / yr |
| 🇦🇺 AU Taxable | 30% | 1.08% | -1.72% | $108 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.13% | -1.67% | $113 / yr |
| 🇫🇷 FR Taxable | 30% | 1.08% | -1.72% | $108 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
BPMC pays quarterly — 4 times per year. Next ex-div: TBD.
How BPMC compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BPMC sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2025-07-17 | 21,353 | — | — | ||
| D-Return | 2025-07-17 | 51,102 | — | — | ||
| D-Return | 2025-07-17 | 25,000 | $61.31 | $1.53M | ||
| D-Return | 2025-07-17 | 25,000 | $43.15 | $1.08M | ||
| D-Return | 2025-07-17 | 10,000 | $15.01 | $150.1K | ||
| U-Tender | 2025-07-17 | 43,175 | — | — | ||
| D-Return | 2025-07-17 | 19,500 | $86.60 | $1.69M | ||
| D-Return | 2025-07-17 | 25,000 | $54.13 | $1.35M | ||
| D-Return | 2025-07-17 | 25,000 | $95.12 | $2.38M | ||
| D-Return | 2025-07-17 | 22,000 | $96.57 | $2.12M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BPMC dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Blueprint Medicines Corporation (BPMC) is currently trading at $129.46, trading near its 52-week high. The current dividend yield is 1.54% based on an annual payout of $2.00 per share.
Blueprint Medicines Corporation (BPMC) is a healthcare stock currently trading at $129.46 with a dividend yield of 1.54%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →